BACKGROUND/AIM: To evaluate the effectiveness of curative (chemo)radiotherapy in patients with nasopharyngeal carcinoma and to identify prognostic factors influencing treatment outcomes. PATIENTS AND METHODS: We conducted a retrospective study of 73 consecutive patients, treated with definitive (chemo)radiotherapy from 2002 to 2019 (median stage III/IV 78%). The median total dose of radiotherapy achieved was 70 Gy. Concomitant chemotherapy was given to 82% of patients. RESULTS: The five- and ten-year locoregional controls were 73% and 72%, respectively; the five- and ten-year distant controls were 93% and 93%, respectively. The five- and ten-year overall survival rates were 46% and 34%, respectively. A multivariate analysis identified age, smoking, and the initial response to treatment as the strongest prognostic factors in predicting survival. CONCLUSION: Smoking ≤5 years before starting curative (chemo)radiotherapy for nasopharyngeal carcinoma was shown to be an independent negative prognostic factor for overall survival with a four-fold higher risk of death compared to non-smokers.

Department of Oncology of the 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital Prague Czech Republic

Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital Prague Czech Republic;

Radiophysics Department of Bulovka University Hospital Prague Czech Republic

Zobrazit více v PubMed

Lee A, Foo W, Mang O, Sze W, Chappell R, Lau W, Ko W. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): An encouraging reduction in both incidence and mortality. International Journal of Cancer. 2021;103(5):680–685. doi: 10.1002/ijc.10894. PubMed DOI

Zhang L, Li Y, Xie S, Ling W, Chen S, Liu Q, Huang Q, Cao S. Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis. Chinese Journal of Cancer. 2021;34(3):350–7. doi: 10.1186/s40880-015-0018-6. PubMed DOI PMC

Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma. American Journal of Clinical Oncology. 2021;25(3):219–223. doi: 10.1097/00000421-200206000-00002. PubMed DOI

Thephamongkhol K. Chemoradiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: a meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14):abstract 5522.

Zhang L, Zhao C, Ghimire B, Hong M, Liu Q, Zhang Y, Guo Y, Huang Y, Guan Z. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials. BMC Cancer. 2021;10(1):558. doi: 10.1186/1471-2407-10-558. PubMed DOI PMC

Langendijk J, Leemans C, Buter J, Berkhof J, Slotman B. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. Journal of Clinical Oncology. 2022;22(22):4604–4612. doi: 10.1200/JCO.2004.10.074. PubMed DOI

Baujat B, Audry H, Bourhis J, Chan A, Onat H, Chua D, Kwong D, Al-Sarraf M, Chi K, Hareyama M, Leung S, Thephamongkhol K, Pignon J. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. International Journal of Radiation Oncology*Biology*Physics. 2019;64(1):47–56. doi: 10.1016/j.ijrobp.2005.06.037. PubMed DOI

Blanchard P, Lee A, Marguet S, Leclercq J, Ng W, Ma J, Chan A, Huang P, Benhamou E, Zhu G, Chua D, Chen Y, Mai H, Kwong D, Cheah S, Moon J, Tung Y, Chi K, Fountzilas G, Zhang L, Hui E, Lu T, Bourhis J, Pignon J. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. The Lancet Oncology. 2018;16(6):645–655. doi: 10.1016/S1470-2045(15)70126-9. PubMed DOI

Bailet J, Mark R, Abemayor E, Lee S, Tran L, Juillard G, Ward P. Nasopharyngeal carcinoma. The Laryngoscope. 2018;102(9):965–972. doi: 10.1288/00005537-199209000-00002. PubMed DOI

Chen C, Han F, Zhao C, Lu L, Sun Y, Liu X, Lu T. Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone. The British Journal of Radiology. 2019;82(978):452–458. doi: 10.1259/bjr/72813246. PubMed DOI

Huang T, Chien C, Tsai W, Liao K, Chou S, Lin H, Dean luo S, Lee T, Lee C, Fang F. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Head Neck. 2021;38(S1):E1026–E1032. doi: 10.1002/hed.24150. PubMed DOI

Sanguineti G, Geara F, Garden A, Tucker S, Ang K, Morrison W, Peters L. Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of local and regional control. International Journal of Radiation Oncology*Biology*Physics. 2019;37(5):985–996. doi: 10.1016/s0360-3016(97)00104-1. PubMed DOI

Johansen L, Mestre M, Overgaard J. Carcinoma of the nasopharynx: Analysis of treatment results in 167 consecutively admitted patients. Head Neck. 2021;14(3):200–207. doi: 10.1002/hed.2880140307. PubMed DOI

Chan A, Leung S, Ngan R, Teo P, Lau W, Kwan W, Hui E, Yiu H, Yeo W, Cheung F, Yu K, Chiu K, Chan D, Mok T, Yau S, Yuen K, Mo F, Lai M, Ma B, Kam M, Leung T, Johnson P, Choi P, Zee B. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. JNCI Journal of the National Cancer Institute. 2019;97(7):536–539. doi: 10.1093/jnci/dji084. PubMed DOI

Yi J, Gao L, Huang X, Li S, Luo J, Cai W, Xiao J, Xu G. Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institution. International Journal of Radiation Oncology*Biology*Physics. 2019;65(1):161–168. doi: 10.1016/j.ijrobp.2005.12.003. PubMed DOI

Wu L, Liu Y, Jiang N, Fan Y, Wen J, Huang S, Guo W, Bian X, Wang F, Li F, Song D, Wu J, Jiang X, Liu J, He X. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: An analysis of 614 patients from a single center. Oral Oncology. 2018;69:26–32. doi: 10.1016/j.oraloncology.2017.03.015. PubMed DOI

Mo Y, Zhang B, Pan Y, Qin Q, Ye Y, Li X, Huang L, Jiang W. Impact of the weekday of the first intensity-modulated radiotherapy treatment on the survival outcomes of patients with nasopharyngeal carcinoma: A multicenter cohort study. Oral Oncology. 2023;116:105258. doi: 10.1016/j.oraloncology.2021.105258. PubMed DOI

Chua M, Tan S, Kusumawidjaja G, Shwe M, Cheah S, Fong K, Soong Y, Wee J, Tan T. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials. European Journal of Cancer. 2018;67:119–129. doi: 10.1016/j.ejca.2016.08.006. PubMed DOI

Lee C, Chu S, Ho H, Lee C, Hung S. Primary tumor volume calculation as a predictive factor of prognosis in nasopharyngeal carcinoma. Acta Oto-Laryngologica. 2019;128(1):93–97. doi: 10.1080/00016480701361921. PubMed DOI

Kam M, Teo P, Chau R, Cheung K, Choi P, Kwan W, Leung S, Zee B, Chan A. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience. International Journal of Radiation Oncology*Biology*Physics. 2019;60(5):1440–1450. doi: 10.1016/j.ijrobp.2004.05.022. PubMed DOI

Lin Y, Huang T, Chien C, Chen H, Hsu H, Huang E, Wang C, Huang Y, Wang Y, Huang C, Chou S, Liao K, Fang F. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy. Radiation Oncology. 2019;13(1):45. doi: 10.1186/s13014-018-0990-5. PubMed DOI PMC

Palazzi M, Orlandi E, Bossi P, Pignoli E, Potepan P, Guzzo M, Franceschini M, Scaramellini G, Cantù G, Licitra L, Olmi P, Tomatis S. Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience. International Journal of Radiation Oncology*Biology*Physics. 2020;74(3):774–780. doi: 10.1016/j.ijrobp.2008.08.068. PubMed DOI

Lin S, Pan J, Han L, Zhang X, Liao X, Lu J. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. International Journal of Radiation Oncology*Biology* Physics. 2018;75(4):1071–1078. doi: 10.1016/j.ijrobp.2008.12.015. PubMed DOI

Loong H, Ma B, Leung S, Mo F, Hui E, Kam M, Chan S, Yu B, Chan A. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiotherapy and Oncology. 2018;104(3):300–304. doi: 10.1016/j.radonc.2011.12.022. PubMed DOI

Li G, Gao J, Liu Z, Tao Y, Xu B, Tu Z, Zhang X, Zeng M, Xia Y. Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: Long-term outcomes of 512 patients from a single institution. Head Neck. 2021;36(5):660–666. doi: 10.1002/hed.23357. PubMed DOI

Gao J, Tao Y, Li G, Yi W, Xia Y. Involvement of difference in decrease of hemoglobin level in poor prognosis of stage I and II nasopharyngeal carcinoma: implication in outcome of radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 2018;82(4):1471–1478. doi: 10.1016/j.ijrobp.2011.05.009. PubMed DOI

Sun W, Zhang L, Luo M, Hu G, Mei Q, Liu D, Long G, Hu G. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Head Neck. 2021;38(S1):E1332–E1340. doi: 10.1002/hed.24224. PubMed DOI

Jiang R, Zou X, Hu W, Fan Y, Yan Y, Zhang M, You R, Sun R, Luo D, Chen Q, Huang P, Hua Y, Guo L, Chen M. The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients. Tumor Biology. 2019;36(10):7775–7787. doi: 10.1007/s13277-015-3505-0. PubMed DOI

Li J, Jiang R, Liu W, Liu Q, Xu M, Feng Q, Chen L, Bei J, Chen M, Zeng Y. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS ONE. 2019;8(12):e83069. doi: 10.1371/journal.pone.0083069. PubMed DOI PMC

Takenaka Y, Kitamura T, Oya R, Ashida N, Shimizu K, Takemura K, Yamamoto Y, Uno A. Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis. PLOS ONE. 2020;12(7):e0181478. doi: 10.1371/journal.pone.0181478. PubMed DOI PMC

He J, Shen G, Ren Z, Qin H, Cui C, Zhang Y, Zeng Y, Jia W. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck. 2021;34(12):1769–1776. doi: 10.1002/hed.22008. PubMed DOI

Peng H, Chen L, Zhang Y, Guo R, Li W, Mao Y, Tan L, Sun Y, Zhang F, Liu L, Tian L, Lin A, Ma J. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Oncotarget. 2020;7(17):24208–24216. doi: 10.18632/oncotarget.8144. PubMed DOI PMC

Jin Y, Yao J, Zhang F, Wang S, Zhang W, Zhou G, Qi Z, Sun Y. Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma. Journal of Cancer. 2017;8(6):976–982. doi: 10.7150/jca.18124. PubMed DOI PMC

Warren G, Kasza K, Reid M, Cummings K, Marshall J. Smoking at diagnosis and survival in cancer patients. International Journal of Cancer. 2021;132(2):401–410. doi: 10.1002/ijc.27617. PubMed DOI

Phipps A, Shi Q, Newcomb P, Nelson G, Sargent D, Alberts S, Limburg P. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III trial N0147. Journal of Clinical Oncology. 2022;31(16):2016–2023. doi: 10.1200/JCO.2012.46.2457. PubMed DOI PMC

Kroeger N, Klatte T, Birkhäuser F, Rampersaud E, Seligson D, Zomorodian N, Kabbinavar F, Belldegrun A, Pantuck A. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer. 2021;118(7):1795–1802. doi: 10.1002/cncr.26453. PubMed DOI

Duffy S, Ronis D, McLean S, Fowler K, Gruber S, Wolf G, Terrell J. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. Journal of Clinical Oncology. 2022;27(12):1969–1975. doi: 10.1200/JCO.2008.18.2188. PubMed DOI PMC

Fortin A, Wang CS, Vigneault E. Influence of smoking and alcohol drinking behaviors on treatment outcomes of patients with squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2009;74(4):1062–1069. doi: 10.1016/j.ijrobp.2008.09.021. PubMed DOI

Browman GP, Wong G, Hodson I, Sathya J, Russell R, McAlpine L, Skingley P, Levine MN. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med. 1993;328(3):159–163. doi: 10.1056/NEJM199301213280302. PubMed DOI

Chen AM, Chen LM, Vaughan A, Sreeraman R, Farwell DG, Luu Q, Lau DH, Stuart K, Purdy JA, Vijayakumar S. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys. 2011;79(2):414–419. doi: 10.1016/j.ijrobp.2009.10.050. PubMed DOI

Rades D, Zwaan I, Janssen S, Yu NY, Schild SE, Idel C, Pries R, Hakim SG, Soror T. Evaluation of the impact of smoking and alcohol consumption on toxicity and outcomes of chemoradiation for head and neck cancer. Anticancer Res. 2023;43(2):823–830. doi: 10.21873/anticanres.16224. PubMed DOI

Pytynia K, Grant J, Etzel C, Roberts D, Wei Q, Sturgis E. Matched-pair analysis of survival of never smokers and ever smokers with squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. 2022;22(19):3981–3988. doi: 10.1200/JCO.2004.02.133. PubMed DOI

Chen A, Chen L, Vaughan A, Farwell D, Luu Q, Purdy J, Vijayakumar S. Head and neck cancer among lifelong never-smokers and ever-smokers. American Journal of Clinical Oncology. 2021;34(3):270–275. doi: 10.1097/COC.0b013e3181dea40b. PubMed DOI

Islami F, Goding Sauer A, Miller K, Siegel R, Fedewa S, Jacobs E, McCullough M, Patel A, Ma J, Soerjomataram I, Flanders W, Brawley O, Gapstur S, Jemal A. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA: A Cancer Journal for Clinicians. 2019;68(1):31–54. doi: 10.3322/caac.21440. PubMed DOI

Shen G, Xu F, He F, Ruan H, Cui C, Chen L, Zeng Y, Jia W. Pretreatment lifestyle behaviors as survival predictors for patients with nasopharyngeal carcinoma. PLoS ONE. 2018;7(5):e36515. doi: 10.1371/journal.pone.0036515. PubMed DOI PMC

Chen C, Shen L, Li B, Gao J, Xia Y. Smoking is a poor prognostic factor for male nasopharyngeal carcinoma treated with radiotherapy. Radiotherapy and Oncology. 2018;110(3):409–415. doi: 10.1016/j.radonc.2013.08.003. PubMed DOI

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. PubMed PMC

Guo S, Huang P, Chen Q, Liu H, Tang L, Zhang L, Liu L, Cao K, Guo L, Mo H, Guo X, Hong M, Mai H. The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy. Radiation Oncology. 2021;9(1):246. doi: 10.1186/s13014-014-0246-y. PubMed DOI PMC

Ouyang P, Su Z, Mao Y, Liang X, Liu Q, Deng W, Xie F. Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma. Cancer Epidemiology, Biomarkers & Prevention. 2022;22(12):2285–2294. doi: 10.1158/1055-9965.EPI-13-0546. PubMed DOI

Seppänen A, Uusitalo AJ. Carboxyhaemoglobin saturation in relation to smoking and various occupational conditions. Ann Clin Res. 1977;9(5):261–268. PubMed

Seppänen A. Smoking in closed space and its effect on carboxyhaemoglobin saturation of smoking and nonsmoking subjects. Ann Clin Res. 1977;9(5):281–283. PubMed

Sørensen LT, Jørgensen S, Petersen LJ, Hemmingsen U, Bülow J, Loft S, Gottrup F. Acute effects of nicotine and smoking on blood flow, tissue oxygen, and aerobe metabolism of the skin and subcutis. J Surg Res. 2009;152(2):224–230. doi: 10.1016/j.jss.2008.02.066. PubMed DOI

Jensen J. Cigarette smoking decreases tissue oxygen. Archives of Surgery. 2023;126(9):1131. doi: 10.1001/archsurg.1991.01410330093013. PubMed DOI

Hoff C. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncologica. 2017;51(4):419–432. doi: 10.3109/0284186X.2011.653438. PubMed DOI

Grau C, Nordsmark M, Khalil A, Horsman M, Overgaard J. Effect of carbon monoxide breathing on hypoxia and radiation response in the SCCVII tumor in vivo. International Journal of Radiation Oncology*Biology*Physics. 2019;29(3):449–454. doi: 10.1016/0360-3016(94)90436-7. PubMed DOI

Mortensen L, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen B, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiotherapy and Oncology. 2018;105(1):14–20. doi: 10.1016/j.radonc.2012.09.015. PubMed DOI

Hoff C, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma – A prospective study. Radiotherapy and Oncology. 2018;103(1):38–44. doi: 10.1016/j.radonc.2012.01.011. PubMed DOI

Yu MC, Ho JH, Lai SH, Henderson BE. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res. 1986;46(2):956–961. PubMed

Bouvier G, Hergenhahn M, Polack A, Bornkamm G, De Thé G, Bartsch H. Characterization of macromolecular lignins as Epstein-Barr virus inducer in foodstuff associated with nasopharyngeal carcinoma risk. Carcinogenesis. 2017;16(8):1879–1885. doi: 10.1093/carcin/16.8.1879. PubMed DOI

Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. International Journal of Cancer. 2021;17(1):1–7. doi: 10.1002/ijc.2910170102. PubMed DOI

Gan YY, Fones-Tan A, Chan SH. Molecular diagnosis of nasopharyngeal carcinoma: a review. Ann Acad Med Singap. 1996;25(1):71–74. PubMed

Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res. 1974;34(5):1189–1191. PubMed

Liu MT, Yeh CY. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC) Radiat Med. 1998;16(2):113–117. PubMed

Wang W, Twu C, Chen H, Jiang R, Wu C, Liang K, Shih Y, Chen C, Lin P, Liu Y, Lin J. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2021;119(5):963–970. doi: 10.1002/cncr.27853. PubMed DOI

Lv J, Chen Y, Zhou G, Tang L, Mao Y, Li W, Guo R, Lin A, Ma J, Sun Y. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study. Oncotarget. 2020;7(13):16806–16817. doi: 10.18632/oncotarget.7609. PubMed DOI PMC

Gurtsevitch VE, Senyuta NB, Ignatova AV, Lomaya MV, Kondratova VN, Pavlovskaya AI, Dushenkina TE, Maximovich DM, Smirnova KV, Mudunov AM, Lichtenstein AV. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions. J Gen Virol. 2017;98(8):2118–2127. doi: 10.1099/jgv.0.000889. PubMed DOI

Xu F, Xiong D, Xu Y, Cao S, Xue W, Qin H, Liu W, Cao J, Zhang Y, Feng Q, Chen L, Li M, Liu Z, Liu Q, Hong M, Shugart Y, Zeng Y, Zeng M, Jia W. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. JNCI: Journal of the National Cancer Institute. 2022;104(18):1396–1410. doi: 10.1093/jnci/djs320. PubMed DOI

Li W, Yang C, Zhao F, Li J, Li Z, Ouyang P, Yuan X, Wu S, Yuan Y, Cui L, Feng H, Lin D, Chen Z, Lu J, Peng X, Chen J. Combination of smoking and Epstein-Barr virus DNA is a predictor of poor prognosis for nasopharyngeal carcinoma: a long-term follow-up retrospective study. BMC Cancer. 2022;22(1):1262. doi: 10.1186/s12885-022-10297-w. PubMed DOI PMC

Holt P. Immune and inflammatory function in cigarette smokers. Thorax. 2023;42(4):241–249. doi: 10.1136/thx.42.4.241. PubMed DOI PMC

Semlali A, Witoled C, Alanazi M, Rouabhia M. Whole cigarette smoke increased the expression of TLRs, HBDs, and proinflammory cytokines by human gingival epithelial cells through different signaling pathways. PLoS ONE. 2019;7(12):e52614. doi: 10.1371/journal.pone.0052614. PubMed DOI PMC

Tollerud D, Clark J, Brown L, Neuland C, Mann D, Pankiw-Trost L, Blattner W, Hoover R. The effects of cigarette smoking on T cell subsets: a population-based survey of healthy Caucasians. American Review of Respiratory Disease. 2013;139(6):1446–1451. doi: 10.1164/ajrccm/139.6.1446. PubMed DOI

Duffy S, Teknos T, Taylor J, Fowler K, Islam M, Wolf G, McLean S, Ghanem T, Terrell J. Health behaviors predict higher Interleukin-6 levels among patients newly diagnosed with head and neck squamous cell carcinoma. Cancer Epidemiology, Biomarkers & Prevention. 2022;22(3):374–381. doi: 10.1158/1055-9965.EPI-12-0987. PubMed DOI PMC

Duffy S, Taylor J, Terrell J, Islam M, Li Y, Fowler K, Wolf G, Teknos T. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2021;113(4):750–757. doi: 10.1002/cncr.23615. PubMed DOI

Zhang G, Tsang C, Deng W, Yip Y, Lui V, Wong S, Cheung A, Hau P, Zeng M, Lung M, Chen H, Lo K, Takada K, Tsao S. Enhanced IL-6/IL-6R signaling promotes growth and malignant properties in EBV-infected premalignant and cancerous nasopharyngeal epithelial cells. PLoS ONE. 2020;8(5):e62284. doi: 10.1371/journal.pone.0062284. PubMed DOI PMC

Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. Journal of Innate Immunity. 2022;3(4):355–364. doi: 10.1159/000325465. PubMed DOI

Lu LM, Zavitz CC, Chen B, Kianpour S, Wan Y, Stämpfli MR. Cigarette smoke impairs NK cell-dependent tumor immune surveillance. J Immunol. 2007;178(2):936–943. doi: 10.4049/jimmunol.178.2.936. PubMed DOI

Onoda N, Nehmi A, Weiner D, Mujumdar S, Christen R, Los G. Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents. Head Neck. 2023;23(10):860–870. doi: 10.1002/hed.1125. PubMed DOI

Porock D, Nikoletti S, Cameron F. The relationship between factors that impair wound healing and the severity of acute radiation skin and mucosal toxicities in head and neck cancer. Cancer Nursing. 2021;27(1):71–78. doi: 10.1097/00002820-200401000-00009. PubMed DOI

Rugg T, Saunders M, Dische S. Smoking and mucosal reactions to radiotherapy. The British Journal of Radiology. 2016;63(751):554–556. doi: 10.1259/0007-1285-63-751-554. PubMed DOI

Al-Mamgani A, Van Rooij P, Mehilal R, Verduijn G, Tans L, Kwa S. Radiotherapy for T1a glottic cancer: the influence of smoking cessation and fractionation schedule of radiotherapy. European Archives of Oto-Rhino-Laryngology. 2019;271(1):125–132. doi: 10.1007/s00405-013-2608-8. PubMed DOI

Khuri F, Lee J, Lippman S, Kim E, Cooper J, Benner S, Winn R, Pajak T, Williams B, Shenouda G, Hodson I, Fu K, Shin D, Vokes E, Feng L, Goepfert H, Hong W. Randomized Phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. JNCI: Journal of the National Cancer Institute. 2019;98(7):441–450. doi: 10.1093/jnci/djj091. PubMed DOI

Nam J, Mclaughlin J, Blot W. Cigarette smoking, alcohol, and nasopharyngeal carcinoma: a case-control study among U.S. Whites. JNCI Journal of the National Cancer Institute. 2017;84(8):619–622. doi: 10.1093/jnci/84.8.619. PubMed DOI

Henderson B, Louie E, Jing J, Buell P, Gardner M. Risk factors associated with nasopharyngeal carcinoma. New England Journal of Medicine. 2020;295(20):1101–1106. doi: 10.1056/NEJM197611112952003. PubMed DOI

Ji X, Zhang W, Xie C, Wang B, Zhang G, Zhou F. Nasopharyngeal carcinoma risk by histologic type in central China: Impact of smoking, alcohol and family history. International Journal of Cancer. 2021;129(3):724–732. doi: 10.1002/ijc.25696. PubMed DOI

Hsu W, Chen J, Chien Y, Liu M, You S, Hsu M, Yang C, Chen C. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan. Cancer Epidemiology, Biomarkers & Prevention. 2022;18(4):1218–1226. doi: 10.1158/1055-9965.EPI-08-1175. PubMed DOI

Righini ChA, Soriano E, Morel N, Hitter A, Bolla M, Reyt E. Traitement par chimiothérapie d’induction et radiothérapie des cancers du cavum de type UCNT (Combined induction chemotherapy and radiotherapy in case of undifferentiated carcinoma of nasopharynx tumours (UCNT)) Rev Laryngol Otol Rhinol (Bord) 2006;127(4):223–228. PubMed

McMillan D. Systemic inflammation, nutritional status and survival in patients with cancer. Current Opinion in Clinical Nutrition and Metabolic Care. 2021;12(3):223–226. doi: 10.1097/MCO.0b013e32832a7902. PubMed DOI

Lo W, Wu C, Wang C, Yang T, Lou P, Ko J, Chang Y. Lymph node ratio predicts recurrence and survival for patients with resectable stage 4 hypopharyngeal cancer. Annals of Surgical Oncology. 2019;24(6):1707–1713. doi: 10.1245/s10434-017-5770-1. PubMed DOI

Sato K, Hatakeyama H, Okada H, Kawano M, Yoshida K, Oki Y, Kuwahara T, Niwa K, Isono Y, Oridate N. Fibrinogen-to-lymphocyte ratio predicts the outcomes of hypopharyngeal squamous cell carcinoma treated with definitive radiotherapy. In Vivo. 2023;37(3):1281–1289. doi: 10.21873/invivo.13206. PubMed DOI PMC